Top 10 Books about Stock Investing to read in 2018. Read more.

CATB - Catabasis Pharmaceuticals

Industry: Biotechnology Sector: Healthcare Exchange: NASDAQ

CATB - Catabasis Pharmaceuticals

Industry: Biotechnology Sector: Healthcare Exchange: NASDAQ

Fri 23'rd Feb 2018

PERIOD 2017-11-24 - 2018-02-23
CHANGE 3.88%
PRICE $1.74





Request Prediction

Catabasis Pharmaceuticals Stock Analysis

Technical stock analysis for Fri 23'rd Feb 2018

Shorts 0.24% ( 2018-01-31 )
Cash 121.4 mill
Loans 18.0 mill
Beta 0.82
ROA -82.35
Buy candidate since 2018-02-22 Gain 3.88%

Catabasis Pharmaceuticals gained 3.88% in the last trading day, rising from $1.68 to $1.74 , and has now gained 3 days in a row. It will be exciting to see whether it manages to continue gaining or take a minor break for the next few days. The price has risen in 5 of the last 10 days and is up by 38.1% over the past 2 weeks. Volume has increased in the last day along with the price, which is a positive technical sign, and, in total, 0.11 million more shares were traded than the day before. In total, 1.47 million shares bought and sold for approximately $2.55 million.

Access today's Top 5 Buy Candidates


Catabasis Pharmaceuticals has broken the very wide and falling short-term trend up. Firstly a slower falling rate is indicated, but this may very well be an early signal of a trend shift. On the reaction there will be support on the roof on the current trend broken, which is $1.58, a level that may pose a second chance to hit a runner. According to fan-theory $1.97 will be the next possible trendtop level and thereby pose a resistance level which may not be broken on the first attempt.

Click here for today's Top 5 Trending Companies


Only positive signals in the chart today. Catabasis Pharmaceuticals holds buy signals from both short- and long-term moving averages. In addition, there is a general buy signal from the relation between the two signals where the short-term average is above the long-term average. On corrections down there will be some support from the lines at $1.56 and $1.49. A break down below any of these levels will issue sell signals. A buy signal was issued from a pivot bottom point on Wednesday February 21, 2018, which indicates further gains until a new top pivot has been found. Volume is rising along with the price. This is considered to be a good technical signal.

Access today's Top 5 Golden Star Companies

Relative Strength Index (RSI)

RSI14 is 64 and the stock is currently not being overbought or oversold

Access full RSI 14 and RSI 21 lists

Support & Resistance

On the downside, the stock finds support just below today's level from accumulated volume at $1.60 and $1.56. On the upside the stock meets some resistance just above today's level from accumulated volume at $1.77, $1.78 and $1.85.

There is natural risk involved when a stock is testing a support level, since if this is broken, the stock then may fall to the next support level. In this case, Catabasis Pharmaceuticals finds support just below today's level at $1.60. If this is broken, then the next support from accumulated volume will be at $1.56 and $1.39. The stock is about to test the resistance from accumulated volume at $1.77 and this may cause the stock to take a minor break or get into a more sideways move for a few days.

Support: $1.60 Price: $1.74 Resistance: $1.77


This stock may move much during a day (volatility) and with a large prediction interval from the Bollinger Band this stock is considered to be "high risk". During the last day, the stock moved $0.19 between high and low, or 11.72%. For the last week, the stock has had a daily average volatility of 13.59%.

Our recommended stoploss: $1.66 (-4.74%) (This stock has high daily movements and this gives high risk. There is a buy signal from pivot bottom found 2 days ago.)

Overall risk:

Very Low Low Medium High Very High


Several short-term signals are positive and the break-up from the falling trend indicates a possible shift for a trend. We believe that the prices around the breaking point will indicate particularly good levels, but we also believe that the current level will hold a possible good buy level for the short-term period.

Trade CATB CFDs with Plus500

Your capital is at risk.

Important: Plus500 doesn't offer signals and it is a CFD service.
Plus500UK Ltd is authorised and regulated by the Financial Conduct Authority (FRN 509909).

Access these features

Auto portfolios gaining up to 30%
Top 5 Candidates in all Lists
Ultimate List Builder
Ad-free browsing

Become a PRO Now

Last donation

Do you find our website useful too?
Help us improve by making a small donation or
Get PRO features